The REFALS trial is studying the effects of oral levosimendan in patients with amyotrophic lateral sclerosis (ALS).
The key risk factor for prostate cancer is the male hormone, testosterone. Without it prostate cancer cannot develop. Other possible factors affecting the development of prostate cancer are described below.
